Back To Search Instructions
Protocols
20 protocol(s) meet the specified criteria
Disease Site: Bladder
Protocol No.TitleStatus
16-2171Multi-Institutional Study to Evaluate DNA Methylation Markers For Detection of Primary Bladder Cancers in Urine Samples From a Cohort of Patients with Hematuria.Open
AMC-095A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid TumorsOpen
CALGB90601-CIRBA Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell CarcinomaOpen (affiliates only)
D6410C00001A Phase I, First-Time-in Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally in Subjects with Solid Tumor CancerOpen
GO29322A Phase Ib Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered with Ipilimumab, Interferon-Alpha, or Other Immune-Modulating Therapies in Patients with Locally Advanced or Metastatic Solid TumorsOpen
LCCC1206PORCH: A Registry of Prospective Outcomes of Radical Cystectomy with or without ChemotherapyOpen
LCCC1209Pilot Study of [18F] Fluorodeoxyglucose Positron Emission Tomography-Magnetic Resonance Imaging (FDG-PET-MRI) for Staging of Muscle-Invasive Bladder CancerOpen
LCCC1517Identifying High-Priority Patient-Centered Outcomes in the Postoperative Cystectomy PeriodOpen
LCCC1538Geriatric Assessment Reporting in Real Time (GARRT) in non-electively hospitalized older cancer patients: feasibility, impact, and clinician acceptance.Open
LCCC1623Interviewing cancer patients and caregivers about using symptom questionnaires to improve quality of cancer careOpen
LCCC1635Pilot study evaluating the microbiome in bladder and prostate cancer patientsOpen
LCCC1636Using PROMIS as part of routine clinical care for racially diverse prostate and bladder cancer patientsOpen
MCC-16962A Phase I Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan, and Temozolomide in Children with Relapsed or Refractory Solid TumorsOpen
ML28897PRO/02My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to one of these Agents.Open
NC-6004-004AA Phase 1b/2 Dose Escalation and Expansion Trial of NC-6004 (Nanoparticle Cisplatin) plus Gemcitabine in Patients with Advanced Solid Tumors or Non-Small Cell Lung Cancer, Biliary Tract, and Bladder CancerOpen
PCRC-14-07Caregiver-­‐guided pain management training in palliative careOpen
RAD-IFN-CS-003A Phase III, Open Label Study to Evaluate the Safety and Efficacy of INSTILADRIN® (rAd-IFN/Syn3) Administered Intravesically to Patients with High Grade, BCG Unresponsive, Non-Muscle Invasive Bladder Cancer (NMIBC).Open
S1314-CIRBA Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder CancerOpen
TC-UT-03-PA Phase 3 Multicenter Trial Evaluating the Efficacy and Safety of MitoGel™ on Ablation of Upper Urinary Tract Urothelial CarcinomaOpen
VANDERBILT001A prospective multi-institutional randomized trial evaluating observation versus immediate surgery in the management of low grade noninvasive bladder cancerOpen